dc.contributor.author | Falegan, Oluyemi S. | |
dc.contributor.author | Egloff, Shanna A. Arnold | |
dc.contributor.author | Zijlstra, Andries | |
dc.contributor.author | Hyndman, M. Eric | |
dc.contributor.author | Vogel, Hans J. | |
dc.date.accessioned | 2020-07-21T22:10:13Z | |
dc.date.available | 2020-07-21T22:10:13Z | |
dc.date.issued | 2019-08 | |
dc.identifier.citation | Falegan, O. S., Arnold Egloff, S. A., Zijlstra, A., Hyndman, M. E., & Vogel, H. J. (2019). Urinary Metabolomics Validates Metabolic Differentiation Between Renal Cell Carcinoma Stages and Reveals a Unique Metabolic Profile for Oncocytomas. Metabolites, 9(8), 155. https://doi.org/10.3390/metabo9080155 | en_US |
dc.identifier.other | eISSN: 2218-1989 | |
dc.identifier.uri | http://hdl.handle.net/1803/10229 | |
dc.description.abstract | Renal cell carcinoma (RCC) is a heterogeneous malignancy which often develops and progresses asymptomatically. Benign oncocytomas are morphologically similar to malignant chromophobe RCC and distinguishing between these two forms on cross-sectional imaging remains a challenge. Therefore, RCC-specific biomarkers are urgently required for accurate and non-invasive, pre-surgical diagnosis of benign lesions. We have previously shown that dysregulation in glycolytic and tricarboxylic acid cycle intermediates can distinguish benign lesions from RCC in a stage-specific manner. In this study, preoperative fasting urine samples from patients with renal masses were assessed by H-1 nuclear magnetic resonance (NMR). Significant alterations in levels of tricarboxylic acid cycle intermediates, carnitines and its derivatives were detected in RCC relative to benign masses and in oncocytomas vs. chromophobe RCC. Orthogonal Partial Least Square Discriminant Analysis plots confirmed stage discrimination between benign vs. pT1 (R2 = 0.42, Q2 = 0.27) and benign vs. pT3 (R2 = 0.48, Q2 = 0.32) and showed separation for oncocytomas vs. chromophobe RCC (R2 = 0.81, Q2 = 0.57) and oncocytomas vs. clear cell RCC (R2 = 0.32, Q2 = 0.20). This study validates our previously described metabolic profile distinguishing benign tumors from RCC and presents a novel metabolic signature for oncocytomas which may be exploited for diagnosis before cross-sectional imaging. | en_US |
dc.description.sponsorship | This research was funded by a research team CRIO grant from Alberta Innovates Health Solutions. HJV was the holder of the Armstrong Chair in molecular cancer research, which was funded in part by the Alberta Cancer Foundation. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Metabolites | en_US |
dc.rights | Copyright © 2019 by the authors.
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). | |
dc.source.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724101/ | |
dc.subject | Metabolomics | en_US |
dc.subject | Renal cell carcinoma | en_US |
dc.subject | Nuclear Magnetic Resonance | en_US |
dc.subject | Oncocytoma | en_US |
dc.subject | Histology | en_US |
dc.title | Urinary Metabolomics Validates Metabolic Differentiation Between Renal Cell Carcinoma Stages and Reveals a Unique Metabolic Profile for Oncocytomas | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.3390/metabo9080155 | |